Logo image of ORMP

ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

NASDAQ:ORMP - Nasdaq - US68403P2039 - Common Stock - Currency: USD

2.32  -0.01 (-0.43%)

After market: 2.32 0 (0%)

Fundamental Rating

3

Overall ORMP gets a fundamental rating of 3 out of 10. We evaluated ORMP against 198 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ORMP as it has an excellent financial health rating, but there are worries on the profitability. ORMP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ORMP had negative earnings in the past year.
ORMP had a negative operating cash flow in the past year.
ORMP had negative earnings in 4 of the past 5 years.
In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

With a decent Return On Assets value of -12.27%, ORMP is doing good in the industry, outperforming 68.69% of the companies in the same industry.
Looking at the Return On Equity, with a value of -13.03%, ORMP is in the better half of the industry, outperforming 76.26% of the companies in the same industry.
Industry RankSector Rank
ROA -12.27%
ROE -13.03%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

ORMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

9

2. Health

2.1 Basic Checks

ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ORMP has less shares outstanding
The number of shares outstanding for ORMP has been increased compared to 5 years ago.
ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 5.54 indicates that ORMP is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.54, ORMP belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.54
ROIC/WACCN/A
WACC8.78%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 25.19 indicates that ORMP has no problem at all paying its short term obligations.
The Current ratio of ORMP (25.19) is better than 97.47% of its industry peers.
A Quick Ratio of 25.19 indicates that ORMP has no problem at all paying its short term obligations.
ORMP's Quick ratio of 25.19 is amongst the best of the industry. ORMP outperforms 97.47% of its industry peers.
Industry RankSector Rank
Current Ratio 25.19
Quick Ratio 25.19
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

ORMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -228.57%.
Looking at the last year, ORMP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ORMP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -30.19% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ORMP. In the last year negative earnings were reported.
Also next year ORMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ORMP's earnings are expected to decrease with -66.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

0

5. Dividend

5.1 Amount

ORMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (4/30/2025, 4:30:02 PM)

After market: 2.32 0 (0%)

2.32

-0.01 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-07 2025-05-07
Inst Owners19.13%
Inst Owner Change-0.39%
Ins Owners13.23%
Ins Owner Change14.21%
Market Cap94.77M
Analysts43.33
Price Target3.32 (43.1%)
Short Float %2.04%
Short Ratio5.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4705.88%
Min EPS beat(2)-9511.76%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)-1716.67%
Min EPS beat(4)-9511.76%
Max EPS beat(4)2449.02%
EPS beat(8)7
Avg EPS beat(8)-793.61%
EPS beat(12)9
Avg EPS beat(12)-529.16%
EPS beat(16)11
Avg EPS beat(16)-398.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)80%
EPS NQ rev (3m)80%
EPS NY rev (1m)41.67%
EPS NY rev (3m)63.16%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS3.58
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.27%
ROE -13.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.19
Quick Ratio 25.19
Altman-Z 5.54
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y60.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.29%
OCF growth 3YN/A
OCF growth 5YN/A